Barbell Medicine Podcast · Barbell Medicine

Episode #391: VO2 Max vs. Cardiorespiratory Fitness, GLP-1 Costs, and the 10,000-Step Myth | Direct Line March 2026 (Free)

·31 min·2 clips

Lilly Direct and Novocare have already lowered cash prices for Zepbound and Wegovy.

1. Barbell Medicine Podcast episode #391 focuses on VO2 max versus cardiorespiratory fitness, GLP-1 costs, and the 10,000-step myth. 2. Dr. Jordan Feigenbaum hosts the monthly Barbell Medicine Direct Line, and Dr. Austin Baraki joins as the co-host answering subscriber questions. 3. The episode asks whether the advice people use to “protect you” is actually doing the opposite for longevity, exercise, and drug access. 4. Feigenbaum says VO2 max and cardiorespiratory fitness are “distinctly different,” and he notes that many cited longevity studies do not directly measure VO2 max. 5. Baraki explains that VO2 max usually requires a maximal metabolic-cart test, while many studies use treadmill tolerance, METS, questionnaires, or other exercise tests. 6. They discuss Dr. Peter Atiyah’s book Outlive and Dr. Eric Topol’s criticism that the evidence base is being collapsed into a single metric. 7. Baraki argues that fitness is the real target, but that focusing only on VO2 max can push people toward narrow protocols that may miss other useful training methods. 8. Feigenbaum compares the issue with strength training, saying that a single benchmark like grip strength or a back squat number captures part of the picture, not all of it. 9. They mention the Barbell Medicine Vital Five and say it includes VO2 max targets plus field tests across different modalities. 10. The discussion turns to GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound, with Feigenbaum asking whether prices will come down. 11. Baraki says GLP-1s are peptides or biologics, which makes generics harder to produce than with simpler drugs. 12. He adds that patent strategies can include the drug, the pen, and other formulation details, and that key patents may not expire until the 2030s. 13. Baraki names Lilly Direct and Novocare as manufacturer programs that have already lowered cash-pay prices in the U.S. 14. He gives current price ranges of about $299 to $449 for Zepbound and about $149 to $349 for Wegovy, and he says those prices dropped most recently in the fall. 15. Feigenbaum says the market is moving because companies are competing, while newer agents such as orforglipron and retatrutide may expand options. 16. The walking question starts with the claim that 7,000 to 12,000 daily steps may be sufficient for health outcomes, and Baraki says “enough” depends on the goal. 17. They trace 10,000 steps to a 1960s Japanese marketing campaign for a pedometer, not to a scientific threshold. 18. Baraki says walking can work if enough of it is done, but he distinguishes mortality benefit from actual gains in cardiorespiratory fitness. 19. The conversation stays conversational and technical, with Feigenbaum and Baraki interrupting each other, pushing back, and using examples from strength training, telemedicine, and the Vital Five. 20. People interested in exercise science, GLP-1 access, and step-count claims will likely get the most from it, while listeners wanting a purely casual chat may skip it.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Barbell Medicine Podcast